Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype

NCT05700565 is registered in ClinicalTrials.gov with Lucie Heinzerling as lead sponsor.

NCT NCT05700565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05700565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype
Lead sponsor
Lucie Heinzerling
Phase
Observational
Overall status
Completed
Start date
January 1, 2022
Completion date
October 1, 2025
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune-related adverse event